{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T17:45:30Z","timestamp":1755798330025,"version":"3.44.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,21]]},"DOI":"10.7759\/cureus.90680","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T16:28:51Z","timestamp":1755793731000},"source":"Crossref","is-referenced-by-count":0,"title":["In Silico Molecular Docking Analysis of Valproic Acid as an Inhibitor of Bruton\u2019s Tyrosine Kinase: Potential Drug Repurposing for Allergies"],"prefix":"10.7759","author":[{"given":"Ricardo E","family":"Martinez-Martinez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Ivan","family":"Calva-Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria M.","family":"Rodriguez-Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo","family":"Soria-Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bibiana P.","family":"Ruiz-Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alma D","family":"Chavez-Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia M","family":"P\u00e9rez-Tapia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia G","family":"Pavano-Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rommel","family":"Chacon-Salinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3690","article-title":"Mast cell secretory granules: armed for battle","volume":"14","author":"Wernersson S","year":"2014","unstructured":"Wernersson S, Pejler G. Mast cell secretory granules: armed for battle. Nat Rev Immunol. 2014, 14:478-94. 10.1038\/nri3690","journal-title":"Nat Rev Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1385\/CRIAI:22:2:107","article-title":"Mast cell growth, differentiation, and death","volume":"22","author":"Gurish MF","year":"2002","unstructured":"Gurish MF, Boyce JA. Mast cell growth, differentiation, and death. Clin Rev Allergy Immunol. 2002, 22:107-18. 10.1385\/CRIAI:22:2:107","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00119","article-title":"Mast cell chemotaxis-chemoattractants and signaling pathways","volume":"3","author":"Halova I","year":"2012","unstructured":"Halova I, Draberova L, Draber P. Mast cell chemotaxis-chemoattractants and signaling pathways. Front Immunol. 2012, 3:119. 10.3389\/fimmu.2012.00119","journal-title":"Front Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00620","article-title":"Mast cell: a multi-functional master cell","volume":"6","author":"Krystel-Whittemore M","year":"2015","unstructured":"Krystel-Whittemore M, Dileepan KN, Wood JG. Mast cell: a multi-functional master cell. Front Immunol. 2015, 6:620. 10.3389\/fimmu.2015.00620","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12634","article-title":"Mast cells as sources of cytokines, chemokines, and growth factors","volume":"282","author":"Mukai K","year":"2018","unstructured":"Mukai K, Tsai M, Saito H, Galli SJ. Mast cells as sources of cytokines, chemokines, and growth factors. Immunol Rev. 2018, 282:121-50. 10.1111\/imr.12634","journal-title":"Immunol Rev"},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.1016\/S1074-7613(01)00157-1","article-title":"Regulation of mast cell survival by IgE","volume":"14","author":"Asai K","year":"2001","unstructured":"Asai K, Kitaura J, Kawakami Y, et al.. Regulation of mast cell survival by IgE. Immunity. 2001, 14:791-800.","journal-title":"Immunity"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.7904","article-title":"Anti-inflammatory effect of dictamnine on allergic rhinitis via suppression of the LYN kinase-mediated molecular signaling pathway during mast cell activation","volume":"37","author":"Liu R","year":"2023","unstructured":"Liu R, Zhang Y, Wang Y, et al.. Anti-inflammatory effect of dictamnine on allergic rhinitis via suppression of the LYN kinase-mediated molecular signaling pathway during mast cell activation. Phytother Res. 2023, 37:4236-50. 10.1002\/ptr.7904","journal-title":"Phytother Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s10719-016-9749-0","article-title":"Mast cell glycosaminoglycans","volume":"34","author":"Mulloy B","year":"2017","unstructured":"Mulloy B, Lever R, Page CP. Mast cell glycosaminoglycans. Glycoconj J. 2017, 34:351-61. 10.1007\/s10719-016-9749-0","journal-title":"Glycoconj J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-009-0052-z","article-title":"Mast cell modulation of the immune response","volume":"9","author":"Ryan JJ","year":"2009","unstructured":"Ryan JJ, Fernando JF. Mast cell modulation of the immune response. Curr Allergy Asthma Rep. 2009, 9:353-9. 10.1007\/s11882-009-0052-z","journal-title":"Curr Allergy Asthma Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s40521-021-00286-y","article-title":"The use of Bruton's tyrosine kinase inhibitors to treat allergic disorders","volume":"8","author":"Dispenza MC","year":"2021","unstructured":"Dispenza MC. The use of Bruton's tyrosine kinase inhibitors to treat allergic disorders. Curr Treat Options Allergy. 2021, 8:261-73. 10.1007\/s40521-021-00286-y","journal-title":"Curr Treat Options Allergy"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9678098","article-title":"Exploring the drug repurposing versatility of valproic acid as a multifunctional regulator of innate and adaptive immune cells","volume":"2019","author":"Soria-Castro R","year":"2019","unstructured":"Soria-Castro R, Schcolnik-Cabrera A, Rodr\u00edguez-L\u00f3pez G, et al.. Exploring the drug repurposing versatility of valproic acid as a multifunctional regulator of innate and adaptive immune cells. J Immunol Res. 2019, 2019:9678098. 10.1155\/2019\/9678098","journal-title":"J Immunol Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.3AB0320-547RR","article-title":"The histone deacetylase inhibitor valproic acid attenuates phospholipase C\u03b32 and IgE-mediated mast cell activation","volume":"108","author":"Rodr\u00edguez-L\u00f3pez GM","year":"2020","unstructured":"Rodr\u00edguez-L\u00f3pez GM, Soria-Castro R, Campillo-Navarro M, et al.. The histone deacetylase inhibitor valproic acid attenuates phospholipase C\u03b32 and IgE-mediated mast cell activation. J Leukoc Biol. 2020, 108:859-66. 10.1002\/JLB.3AB0320-547RR","journal-title":"J Leukoc Biol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.9734\/irjpac\/2021\/v22i330396","article-title":"A review on molecular docking","volume":"22","author":"Denyandev","year":"2021","unstructured":"Denyandev, K. A review on molecular docking. Int Res J Pure Appl Chem. 2021, 22:60-8. 10.9734\/irjpac\/2021\/v22i330396","journal-title":"Int Res J Pure Appl Chem"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.69576","article-title":"In silico evaluation of HIV protease and RNA polymerase inhibitors as potential COVID-19 therapeutics","volume":"16","author":"Devaraji M","year":"2024","unstructured":"Devaraji M, Ravikumar L. In silico evaluation of HIV protease and RNA polymerase inhibitors as potential COVID-19 therapeutics. Cureus. 2024, 16:e69576. 10.7759\/cureus.69576","journal-title":"Cureus"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.67808","article-title":"In silico analysis of bioactive compounds from leaves of Abrus precatorius L. (rosary pea) against breast cancer","volume":"16","author":"Baskaran H","year":"2024","unstructured":"Baskaran H, Margesan T, Raju K. In silico analysis of bioactive compounds from leaves of Abrus precatorius L. (rosary pea) against breast cancer. Cureus. 2024, 16:e67808. 10.7759\/cureus.67808","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.1021\/acsmedchemlett.0c00249","article-title":"Stereochemical differences in fluorocyclopropyl amides enable tuning of Btk inhibition and off-target activity","volume":"11","author":"Crawford JJ","year":"2020","unstructured":"Crawford JJ, Lee W, Johnson AR, et al.. Stereochemical differences in fluorocyclopropyl amides enable tuning of Btk inhibition and off-target activity. ACS Med Chem Lett. 2020, 11:1588-97.","journal-title":"ACS Med Chem Lett"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1021\/ci200454v","article-title":"Combining global and local measures for structure-based druggability predictions","volume":"52","author":"Volkamer A","year":"2012","unstructured":"Volkamer A, Kuhn D, Grombacher T, Rippmann F, Rarey M. Combining global and local measures for structure-based druggability predictions. J Chem Inf Model. 2012, 52:360-72. 10.1021\/ci200454v","journal-title":"J Chem Inf Model"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0313-y","article-title":"Second-generation inhibitors of Bruton tyrosine kinase","volume":"9","author":"Wu J","year":"2016","unstructured":"Wu J, Liu C, Tsui ST, Liu D. Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol. 2016, 9:80. 10.1186\/s13045-016-0313-y","journal-title":"J Hematol Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-060410-105819","article-title":"Correlating structure and energetics in protein-ligand interactions: paradigms and paradoxes","volume":"82","author":"Martin SF","year":"2013","unstructured":"Martin SF, Clements JH. Correlating structure and energetics in protein-ligand interactions: paradigms and paradoxes. Annu Rev Biochem. 2013, 82:267-93. 10.1146\/annurev-biochem-060410-105819","journal-title":"Annu Rev Biochem"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01123-6","article-title":"BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib","volume":"35","author":"Estupi\u00f1\u00e1n HY","year":"2021","unstructured":"Estupi\u00f1\u00e1n HY, Wang Q, Bergl\u00f6f A, et al.. BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib. Leukemia. 2021, 35:1317-29. 10.1038\/s41375-021-01123-6","journal-title":"Leukemia"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184331","article-title":"Molecular docking: shifting paradigms in drug discovery","volume":"20","author":"Pinzi L","year":"2019","unstructured":"Pinzi L, Rastelli G. Molecular docking: shifting paradigms in drug discovery. Int J Mol Sci. 2019, 20:4331. 10.3390\/ijms20184331","journal-title":"Int J Mol Sci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008821","article-title":"BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib","volume":"7","author":"Bonfiglio S","year":"2023","unstructured":"Bonfiglio S, Sutton LA, Ljungstr\u00f6m V, et al.. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib. Blood Adv. 2023, 7:2794-806. 10.1182\/bloodadvances.2022008821","journal-title":"Blood Adv"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1098\/rsos.210066","article-title":"A mechanism for localized dynamics-driven activation in Bruton's tyrosine kinase","volume":"8","author":"Qiu S","year":"2021","unstructured":"Qiu S, Liu Y, Li Q. A mechanism for localized dynamics-driven activation in Bruton's tyrosine kinase. R Soc Open Sci. 2021, 8:210066. 10.1098\/rsos.210066","journal-title":"R Soc Open Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)80417-3","article-title":"Regulation of Btk function by a major autophosphorylation site within the SH3 domain","volume":"4","author":"Park H","year":"1996","unstructured":"Park H, Wahl MI, Afar DE, et al.. Regulation of Btk function by a major autophosphorylation site within the SH3 domain. Immunity. 1996, 4:515-25. 10.1016\/s1074-7613(00)80417-3","journal-title":"Immunity"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1243970","article-title":"ReverseDock: a web server for blind docking of a single ligand to multiple protein targets using AutoDock Vina","volume":"10","author":"Krause F","year":"2023","unstructured":"Krause F, Voigt K, Di Ventura B, \u00d6zt\u00fcrk MA. ReverseDock: a web server for blind docking of a single ligand to multiple protein targets using AutoDock Vina. Front Mol Biosci. 2023, 10:1243970. 10.3389\/fmolb.2023.1243970","journal-title":"Front Mol Biosci"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton's tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh S","year":"2018","unstructured":"Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton's tyrosine kinase in B cells and malignancies. Mol Cancer. 2018, 17:57. 10.1186\/s12943-018-0779-z","journal-title":"Mol Cancer"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S288550","article-title":"Bruton's tyrosine kinase inhibition for the treatment of rheumatoid arthritis","volume":"10","author":"Arneson LC","year":"2021","unstructured":"Arneson LC, Carroll KJ, Ruderman EM. Bruton's tyrosine kinase inhibition for the treatment of rheumatoid arthritis. Immunotargets Ther. 2021, 10:333-42. 10.2147\/ITT.S288550","journal-title":"Immunotargets Ther"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/molecules20021984","article-title":"Theory and applications of covalent docking in drug discovery: merits and pitfalls","volume":"20","author":"Kumalo HM","year":"2015","unstructured":"Kumalo HM, Bhakat S, Soliman ME. Theory and applications of covalent docking in drug discovery: merits and pitfalls. Molecules. 2015, 20:1984-2000. 10.3390\/molecules20021984","journal-title":"Molecules"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11080764","article-title":"Non-covalent BTK inhibitors-the new BTKids on the block for B-cell malignancies","volume":"11","author":"Lewis KL","year":"2021","unstructured":"Lewis KL, Cheah CY. Non-covalent BTK inhibitors-the new BTKids on the block for B-cell malignancies. J Pers Med. 2021, 11:764. 10.3390\/jpm11080764","journal-title":"J Pers Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.127566","article-title":"Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity","volume":"4","author":"Wang S","year":"2019","unstructured":"Wang S, Mondal S, Zhao C, et al.. Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity. JCI Insight. 2019, 4:e127566. 10.1172\/jci.insight.127566","journal-title":"JCI Insight"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01049-7","article-title":"Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies","volume":"14","author":"Gu D","year":"2021","unstructured":"Gu D, Tang H, Wu J, Li J, Miao Y. Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies. J Hematol Oncol. 2021, 14:40. 10.1186\/s13045-021-01049-7","journal-title":"J Hematol Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/382385-in-silico-molecular-docking-analysis-of-valproic-acid-as-an-inhibitor-of-brutons-tyrosine-kinase-potential-drug-repurposing-for-allergies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T16:28:52Z","timestamp":1755793732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/382385-in-silico-molecular-docking-analysis-of-valproic-acid-as-an-inhibitor-of-brutons-tyrosine-kinase-potential-drug-repurposing-for-allergies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.90680","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,21]]}}}